硝酰基(HNO)，新一代心力衰竭治疗正性肌力药物

doi:10.15302/J-ENG-2015118

PDF(186 KB)

工程（英文） ›› 2015, Vol. 1 ›› Issue (4) : 401-404. DOI: 10.15302/J-ENG-2015118

新闻热点

News & Highlights

硝酰基(HNO)，新一代心力衰竭治疗正性肌力药物

作者信息 +

Nitroxyl, a New Generation of Positive Inotropic Agent for Heart Failure

Author information +

History +

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

. . Engineering. 2015, 1(4): 401-404 https://doi.org/10.15302/J-ENG-2015118

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	D. A. Kass, R. J. Solaro. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation, 2006, 113(2): 305–315
[2]	M. Wang, R. Mazhari, I. Ilsar, A. Wang, M. S. Sabbah, H. N. Sabbah. Intravenous infusion of CXL-1020, a novel nitroxyl (HNO) donor, improves left ventricular systolic and diastolic function in dogs with advanced heart failure. J. Card. Fail., 2009, 15(6 Suppl): S73–S74
[3]	S. Daya, R. Mazhari, R. S. Tunin, D. A. Kass. Intravenous infusion of novel HNO donor, CXL-1020, improves left ventricular contractile function in normal and failing dogs. J. Card. Fail., 2009, 15(6 Suppl): S75
[4]	J. M. Fukuto, M. I. Jackson, N. Kaludercic, N. Paolocci. Examining nitroxyl in biological systems. Meth. Enzymol., 2008, 440: 411–431
[5]	C. G. Tocchetti, Playing with cardiac “redox switches”: The “HNO way” to modulate cardiac function. Antioxid. Redox Signal., 2011, 14(9): 1687–1698
[6]	J. M. Fukuto, K. Chiang, R. Hszieh, P. Wong, G. Chaudhuri. The pharmacological activity of nitroxyl: A potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther., 1992, 263(2): 546–551
[7]	N. Paolocci, Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc. Natl. Acad. Sci. USA, 2001, 98(18): 10463–10468
[8]	N. Paolocci, Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: Independence from β-adrenergic signaling. Proc. Natl. Acad. Sci. USA, 2003, 100(9): 5537–5542
[9]	A. Fabiato. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am. J. Physiol., 1983, 245(1): C1–C14
[10]	G. A. Krudy, Q. Kleerekoper, X. Guo, J. W. Howarth, R. J. Solaro, P. R. Rosevear. NMR studies delineating spatial relationships within the cardiac troponin I-troponin C complex. J. Biol. Chem., 1994, 269(38): 23731–23735
[11]	Q. Kleerekoper, J. W. Howarth, X. Guo, R. J. Solaro, P. R. Rosevear. Cardiac troponin I induced conformational changes in cardiac troponin C as monitored by NMR using site-directed spin and isotope labeling. Biochemistry, 1995, 34(41): 13343–13352
[12]	W. J. Dong, J. M. Robinson, S. Stagg, J. Xing, H. C. Cheung. Ca²⁺-induced conformational transition in the inhibitory and regulatory regions of cardiac troponin I. J. Biol. Chem., 2003, 278(10): 8686–8692
[13]	C. G. Tocchetti, Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca²⁺ cycling. Circ. Res., 2007, 100(1): 96–104
[14]	M. J. Kohr, Nitroxyl enhances myocyte Ca²⁺ transients by exclusively targeting SR Ca²⁺-cycling. Front. Biosci. (Elite Ed.), 2010, E2(2): 614–626
[15]	J. P. Froehlich, Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry, 2008, 47(50): 13150–13152
[16]	T. Dai, Nitroxyl increases force development in rat cardiac muscle. J. Physiol. (Lond.), 2007, 580(3): 951–960
[17]	W. D. Gao, Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ. Res., 2012, 111(8): 1002–1011
[18]	N. G. MacFarlane, D. J. Miller. Depression of peak force without altering calcium sensitivity by the superoxide anion in chemically skinned cardiac muscle of rat. Circ. Res., 1992, 70(6): 1217–1224
[19]	W. D. Gao, Y. Liu, E. Marban. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation, 1996, 94(10): 2597–2604
[20]	M. Canton, Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur. Heart J., 2006, 27(7): 875–881
[21]	N. Paolocci, The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the Janus face of NO. Pharmacol. Ther., 2007, 113(2): 442–458
[22]	F. J. Giordano. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest., 2005, 115(3): 500–508
[23]	M. Seddon, Y. H. Looi, A. M. Shah. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart, 2007, 93(8): 903–907
[24]	G. W. Dorn II. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol. Rev., 2010, 90(3): 1013–1062
[25]	J. G. Duncan, R. Ravi, L. B. Stull, A. M. Murphy. Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(4): H1512–H1518
[26]	J. van der Velden. Functional significance of myofilament protein oxidation. Eur. Heart J., 2006, 27(7): 764–765
[27]	Z. Hertelendi, Oxidation of myofilament protein sulfhydryl groups reduces the contractile force and its Ca²⁺ sensitivity in human cardiomyocytes. Antioxid. Redox Signal., 2008, 10(7): 1175–1184
[28]	E. R. Stadtman, R. L. Levine. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids, 2003, 25(3−4): 207–218
[29]	H. N. Sabbah, Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. Circ. Heart Fail., 2013, 6(6): 1250–1258
[30]	F. I. Malik, Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science, 2011, 331(6023): 1439–1443